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ApoptosisOxidative stress is implicated as an important molecular mechanism underlying ﬁbrosis in a variety of organs,
including the lungs. However, the causal role of reactive oxygen species (ROS) released from environmental
exposures and inﬂammatory/interstitial cells in mediating ﬁbrosis as well as how best to target an imbalance
in ROS production in patients with ﬁbrosis is not ﬁrmly established. We focus on the role of ROS in pulmonary
ﬁbrosis and, where possible, highlight overlapping molecular pathways in other organs. The key origins of
oxidative stress in pulmonary ﬁbrosis (e.g. environmental toxins, mitochondria/NADPH oxidase of inﬂamma-
tory and lung target cells, and depletion of antioxidant defenses) are reviewed. The role of alveolar epithelial
cell (AEC) apoptosis by mitochondria- and p53-regulated death pathways is examined. We emphasize an
emerging role for the endoplasmic reticulum (ER) in pulmonary ﬁbrosis. After brieﬂy summarizing how
ROS trigger a DNA damage response, we concentrate on recent studies implicating a role for mitochondrial
DNA (mtDNA) damage and repair mechanisms focusing on 8-oxoguanine DNA glycosylase (Ogg1) as well
as crosstalk between ROS production, mtDNA damage, p53, Ogg1, and mitochondrial aconitase (ACO2). Final-
ly, the association between ROS and TGF-β1-induced ﬁbrosis is discussed. Novel insights into the molecular
basis of ROS-induced pulmonary diseases and, in particular, lung epithelial cell death may promote the devel-
opment of unique therapeutic targets for managing pulmonary ﬁbrosis as well as ﬁbrosis in other organs and
tumors, and in aging; diseases for which effective management is lacking. This article is part of a Special Issue
entitled: Fibrosis: Translation of basic research to human disease.
Published by Elsevier B.V.1. Introduction
Fibrosis is characterized by exuberant extracellular matrix (ECM)
protein deposition in the basement membrane and interstitial tissue
in the setting of an injured overlying epithelium and expansion of
activated mesenchymal cells (myoﬁbroblasts). Fibrosis is pathologi-
cally evident in numerous diseases involving nearly every organ.
Accumulating evidence over the past several decades have identiﬁed
many of the important pathogenic mechanisms that promote ﬁbrosis,
yet the precise molecular mechanisms involved and the crosstalk
between implicated pathways are not fully understood. Oxidative
stress is one important molecular mechanism underlying ﬁbrosis in a
variety of organs, including the lungs. However, the causal role ofolar epithelial type II; AM, alveolar
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best to target an imbalance in ROS production in patients with ﬁbrosis
are not ﬁrmly established.
The term “oxidative stress” encompasses all the molecular, cellular
and tissue abnormalities resulting from excess ROS production and/or
depleted antioxidant defenses [1–3]. As compared to other organs, the
lungs are particularly vulnerable to oxidative stress because they are
exposed to the highest levels of oxygen; oxygen pressure of inhaled
air is 150 mm Hg and that of alveolar air is 100 mm Hg while venous
blood oxygen pressures returning from various other organs range
from as high as ~45 mm Hg to as low as ~1 mm Hg [2]. As emphasized
by others, the traditional concept ofﬁbrosis resulting froman imbalancemacrophage; ARE, antioxidant response element; BALF, bronchoalveolar lavage ﬂuid;
atrix; EMT, epithelial–mesenchymal transition; ERK, extracellular-signal-regulated ki-
kinase 1 alpha; IL-1β, interleukin-1 beta; ACO2, mitochondrial aconitase; mtDNA, mi-
, mitochondrial membrane potential; MDM2, mouse double-minute 2 protein; NAC,
hase; Nrf2, nuclear factor erythroid 2-related factor 2; PKCδ, protein kinase C delta;
uscle actin; O2−, superoxide; SOD, superoxide dismutase; SP-C, surfactant protein C;
protein response; XBP1, X-box binding protein 1
uman disease.
y Feinberg School of Medicine, McGawM-330, 240 E. Huron St., Chicago, IL 60611-3010,
1029P. Cheresh et al. / Biochimica et Biophysica Acta 1832 (2013) 1028–1040in ROS production and antioxidant defenses is overly simplistic given
the diverse pathways that are independently regulated and the ineffec-
tual results from numerous antioxidant trials [1–3].
The purpose of this review is to highlight our current understand-
ing of the causal role of oxidative stress in promoting ﬁbrosis. Given
the enormity of the topic and space constraints, we have chosen to
restrict our focus to the role of ROS in mediating pulmonary ﬁbrosis.
In particular, we emphasize the role of ROS in the pathobiology of
asbestosis, which is pulmonary ﬁbrosis resulting from asbestos
exposure. Asbestosis shares radiographic and pathologic features
with idiopathic pulmonary ﬁbrosis (IPF), a much more common
disease that has a worse prognosis, and lacks effective treatment
and ideal animal models. We underscore some of the important
overlapping oxidative stress-induced molecular pathways resulting
in ﬁbrosis in other organs (e.g. liver, heart, etc.) that have recently
been reviewed in detail elsewhere [4–6]. We ﬁrst describe the
principal origins of oxidative stress that can lead to pulmonary
ﬁbrosis including environmental toxins (e.g. tobacco, occupational
exposure such as asbestos or silica, radiation, and drugs, such as
bleomycin), mitochondria and NADPH oxidase (NOX), especially
NADPH oxidase-4 (NOX4) in inﬂammatory and lung target cells.
Oxidative stress also results from inadequate or deﬁcient antioxidant
defenses. Reactive nitrogen species, which are beyond the scope of
this review, also contribute to the free radical burden of ﬁbrotic
lungs (see for review: [7]). We explore the evidence for alveolar
epithelial cell (AEC) apoptosis being important in promoting
asbestosis and IPF with an emphasis on ROS derived from the
mitochondria- and p53-regulated death pathways as well as recent
evidence for an activated endoplasmic reticulum (ER) stress
response in patients with IPF. After brieﬂy summarizing how
ROS trigger a DNA damage response, we discuss the role for mito-
chondrial DNA (mtDNA) damage and repair mechanisms focusing
on 8-oxoguanine DNA glycosylase (Ogg1) as well as crosstalk
between ROS production, mtDNA damage, p53, Ogg1, and mito-
chondrial aconitase (ACO2), which is a mitochondrial redox-
sensor molecule involved in mtDNA maintenance. Finally, the as-
sociation between oxidative stress and transforming growth factor
β (TGF-β)-induced ﬁbrosis is discussed. We examine recent inves-
tigations highlighting important crosstalk between ROS, apoptosis,
and inﬂammation. A general hypothetical model depicting the
major ROS-driven pathways described in this review is illustrated
in Fig. 1. Collectively, these studies are revealing new insights into
the molecular basis of ROS-induced pulmonary ﬁbrosis and that
may prove useful in the development of novel anti-ﬁbrotic treat-
ment strategies.
2. Origins of oxidative stress in pulmonary ﬁbrosis
Biological systems are continually exposed to both extrinsic
sources of reactive oxidants (e.g. tobacco, asbestos/silica, radiation,
bleomycin and other drugs, etc.) and those that arise endogenously
in inﬂammatory cells as well as epithelial, mesenchymal and endo-
thelial cells within tissues [8]. Several enzymatic systems contribute
to ROS production including NOXs, xanthine oxidase, nitric oxide
synthase (NOS), and the mitochondrial electron transport chain
[8,9]. They are also produced from themetabolism of a wide spectrum
of drugs and xenobiotics [8]. ROS, including superoxide (O2−) and hy-
drogen peroxide (H2O2), play a central role in host defense by killing
microbes in phagocytic cells. Although excess amounts of ROS are
toxic and can promote ﬁbrosis, lower levels of ROS are ‘physiologic’
by functioning as signaling molecules that mediate various cellular
responses including proliferation, migration, differentiation, and
gene expression [7–9]. The highly reactive HO• can be generated
from O2− and H2O2 in the presence of small amounts of redox-
activate ferrous iron complexed with toxins such as asbestos ﬁber
from outside of cell, via the Fenton-catalyzed Haber–Weiss reactionshown in Eq. (1) [9,10]. Alkoxyl radicals are also formed by iron catal-
ysis of organic hydroperoxides as shown in Eq. (2).
O−2 þ H2O2 →
iron
HO− þHO•þ O2 ð1Þ
Fe
2þ þ ROOH→Fe3þ þ RO• þ HO− ð2Þ
Redox cycling is a common mechanism by which quinones and related
species are reduced by a ﬂavoenzyme (e.g. cytochrome P450 reductase)
to a free radical that then reacts with oxygen to generate O2− [9]. Some
ﬁbrogenic agents implicated in redox cycling include the herbicide
paraquat, the anticancer drug doxorubicin and the diabetogenic com-
pound alloxan [8]. Free radicals also arise through the oxidation of phe-
nols, aromatic amines and hydrazines by heme proteins, and some
compounds undergo autoxidation catalyzed by transition metal ions
[9,11]. Because these ROS-producing reactions are associated with ﬁ-
brosis, they have been the focus of investigative interest [10]. Finally,
as reviewed in this section, oxidative stress can also be caused by deple-
tion of antioxidant defense mechanisms, resulting in increased levels of
ROS. In general, low levels of ROS production can result in cell prolifer-
ation and activation of antioxidant defenses, but higher ROS levels trig-
ger DNA damage, p53 activation, cell cycle blockade, and cell death via
apoptosis and/or necrosis; all of these may be important in a culminat-
ing ﬁbrotic response.
At least 4 lines of evidence convincingly show that ROS generated
internally or induced by environmental exposure play a vital role in
the development of pulmonary ﬁbrotic diseases as reviewed else-
where [1,7,12–14]: (1) Oxidized proteins and lipid products like 8-
isoprostrane and carbonylated proteins have been identiﬁed in exhaled
air, bronchoalveolar lavage ﬂuid, and lung tissue from patients with
ﬁbrotic lung diseases. (2) Bleomycin-induced pulmonary ﬁbrosis, the
most commonly utilized experimental model, is associated withmarked
increases in the levels of ROS, oxidized proteins, DNA and lipids. (3)
Increased oxidative DNA damage is detected in patients with IPF as
well as workers with silicosis and asbestosis and animal models with
silica or asbestos induced lung ﬁbrosis. (4) Antioxidants and iron chela-
tors can attenuate bleomycin- and asbestos-induced pulmonary ﬁbrosis
in rodent models.
2.1. Mitochondria-derived ROS
ROS generated from the mitochondria of key target cells appear
important in mediating pulmonary ﬁbrosis. Mitochondrial dysfunc-
tion results in the generation of ROS (e.g. H2O2 and O2−) as the
electron transport chain is uncoupled from proton pumping and
ROS are released into the cytosol [15]. Carter and associates [16–19]
have established a key role for H2O2 production by the mitochondria
of alveolar macrophages (AM) in causing asbestosis. They reported
that AM exposed to asbestos ﬁbers produces H2O2, which is blocked
by catalase or mitigation of AM mitochondrial stress. Further, Rac1,
a Rho GTP binding protein family member, increases AM mitochon-
drial H2O2 production while asbestos-induced AM H2O2 production
is reduced by knockdown of the iron–sulfur protein of complex III
in the mitochondrial electron transport chain, a major site or ROS
production. Increased levels of Rac1 are localized in the mitochondria
of AM of asbestosis patients, and asbestos exposed mice with a condi-
tional deletion of Rac1 have less oxidative stress and pulmonary
ﬁbrosis [16–19] (Fig. 2). Taken together, these studies demonstrate
that asbestos triggers AM H2O2 production by transferring electrons
from complex III to Rac1, which then drive down-stream signaling
pathways, inﬂammation and cellular injury that result in asbestosis
in mice. Carter et.al have proposed that Rac1 is a novel biomarker
for pulmonary ﬁbrosis. An important role for H2O2 mediating pulmo-
nary ﬁbrosis is also supported by the protective effects of catalase in a
rodent model of asbestosis [20]. As reviewed elsewhere, exogenous
Fig. 1. Hypothetical model of environmental stress/oxidant induced pulmonary ﬁbrosis. Environmental toxins/oxidants may induce the generation of ROS via induction of ER stress,
NOX4 and uncoupling of mitochondrial electron transport or Rac 1 mediated activation of macrophages and/or PMNs. In conjunction with DNA damage and p53 activation, ROS
promote apoptosis of airway epithelial cells, and elicit the production of cytokines and growth factors that may be important for invasive myoﬁbroblastic differentiation and col-
lagen deposition and may alter antioxidant defenses. The susceptibility of epithelial cells to apoptosis may be affected by mutations in surfactant, telomerase and mucin genes.
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tion in other important lung target cells implicated in pulmonary
ﬁbrosis, including epithelial cells [14,21]. However, additional studies
are warranted to better understand the relevance of these ﬁndings in
pulmonary ﬁbrosis and to determine which cell should be primarily
targeted.
2.2. NAD(P)H oxidase
NOX family of oxidoreductases catalyzes one or two electron
reductions to form O2− and H2O2, which contribute to cellular signaling,
killing of invading microbes, and damage of surrounding host tissues
when released primarily by activated inﬂammatory cells but also by
non-inﬂammatory cells (see for reviews: [22,23]). Recent studies have
established the central role of NOX, especially isoforms NOX1, NOX2
and NOX4, in the pathogenesis of pulmonary ﬁbrosis [22,23]. NOX4 is
induced by TGF-β1, which subsequently promotes key events in the
development of ﬁbrotic lung disease such as myoﬁbroblast differentia-
tion and impaired re-epithelialization discussed later (see Section 5).
Thannickal and colleagues [24] demonstrated that NOX4-dependent
generation ofH2O2 is required for TGF-β1-inducedmyoﬁbroblast differ-
entiation and ECMproduction, and that genetic knockdown or pharma-
cologic inhibition of NOX4 prevents bleomycin-induced ﬁbrosis inmice.
Moreover, NOX-4 is upregulated in lungs of mice treated with
bleomycin and humans with IPF [24]. TGF-β1 mediated myoﬁbroblast
differentiation is associated with the enzymatic production of extracel-
lular H2O2 that can promote AEC death, a key event initiating and
perpetuating pulmonary ﬁbrosis as reviewed in Section 3.1 [25,26].
NOX4 is strongly expressed in the hyperplastic alveolar epithelium of
IPF patients, particularly in alveolar type 2 (AT2) cells [25]. Interesting-
ly, NOX4-deﬁcient mice are completely protected against bleomycin-
induced AT2 cell apoptosis and pulmonary ﬁbrosis, but not against
bleomycin-induced pulmonary inﬂammation [25]. NOX-4 deﬁcient
epithelial cells and/or AEC treated with NOX-4 chemical inhibitors(ﬂuvene-5- inhibits NOX-4/2- and GK13601- inhibits NOX-1/4)
decrease TGF-β1-mediated ROS generation and AEC apoptosis [25].
Collectively, these ﬁndings ﬁrmly implicate that ROS produced by
NOX4 are crucial for mediating AEC apoptosis during the development
of pulmonary ﬁbrosis. In an experimental model of diabetic lung ﬁbro-
sis, NOX activation in ﬁbroblasts by angiotensin II also appears impor-
tant [27]. A role of NOX2 in pulmonary ﬁbrosis is supported by the
ﬁnding that mice genetically deﬁcient in NOX2 are protected from
bleomycin- or carbon nanotube-induced lung ﬁbrosis [22,28].
NOXs are also important in mediating ﬁbrosis in other organs. For
example, a mutated SOD, which enhances O2− production, increases
NOX1 in hepatic stellate cells during liver ﬁbrosis [29]. Hepatocyte
apoptosis and liver ﬁbrosis are attenuated by GKT137831, an inhibi-
tor of NOX4/NOX1, in vivo [29,30]. In the heart, NOX4 is also implicat-
ed in promoting myoﬁbroblastic differentiation of cardiac ﬁbroblasts
and is a major source of mitochondrial oxidative stress in cardiac
myocytes in the failing heart [31,32]. Taken together, these data ﬁrm-
ly support a causal role of NOXs in tissue ﬁbrogenesis and indicates
that targeting NOXs could afford a novel approach to treatment of
ﬁbrogenic diseases. Future studies are necessary to further character-
ize the primary source of NOXs and the role of NOX family members
in the setting of ROS-induced organ ﬁbrosis. It will also be of interest
to determine the translational signiﬁcance of targeting NOXs in
humans with various forms of ﬁbrosis.
Oxidative stress by NOXs and mitochondria-derived ROS can also
trigger inﬂammatory signaling via the Nalp3 inﬂammosome sensing
that may be important in driving silicosis, asbestosis and perhaps
other forms of ﬁbrosis [33–36]. The inﬂammosome, which is primarily
expressed within macrophages and neutrophils, is a protein complex
that serves as a host defense cellular danger sensor by activating
IL-1β-driven innate pathway. Studies using pharmacologic ROS inhibi-
tors, iron chelated asbestos, and targeted murine knockouts, demon-
strate that ROS generated by NOXs during phagocytosis and/or by
mitochondrial oxidative phosphorylation, are essential for activation
Fig. 2. Asbestos-induced pulmonary ﬁbrosis is blocked in Rac-1 null mice. Wild-type
(WT) and Rac1 null mice were intratracheally exposed to chrysotile asbestos
(100 μg). Micro-CT scan images were obtained on live mice (in vivo) 21 days after ex-
posure. Images are representative of three WT (A) and three Rac1 null (B) mice. Twen-
ty one days after exposure, the mice were euthanized and the lungs were removed and
processed for collagen deposition using Masson's trichrome staining. Micrographs are
representative of 10 WT (C) and 10 Rac1 null (D) mice. (E) Mice were euthanized
21 days after exposure, and lungs were removed and homogenized for hydroxyproline
assay. WT (n=4) and Rac1 null (n=4); *pb0.0208.
Experimental data from Osborn-Heaford et. [16] was used with permission.
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silica and asbestos, induce oxidative stress from NOXs and/or the
mitochondria of inﬂammatory cells thereby activatingmultiple signaling
pathways, including Nalp3, which may represent another novel thera-
peutic target for the remediation of pulmonary ﬁbrosis.2.3. Depletion of antioxidant defense mechanisms
All organs, including the lungs, express a wide variety of antioxi-
dants to protect against oxidative stress. Depletion of antioxidant
defenses can result in oxidative stress that augments ﬁbrosis. Herein,
we focus on some of the primary lung antioxidant defenses implicat-
ed in animal models of pulmonary ﬁbrosis and humans with IPF,
including catalase, glutathione (GSH), and superoxide dismutase
(SOD) as well as nuclear factor erythroid 2-related factor 2 (Nrf2),
the primary regulator of antioxidant enzymes.2.3.1. Catalase
Catalase, a scavenger of H2O2 expressed in lung AEC and inﬂam-
matory cells, can inhibit H2O2-mediated activation of ﬁbroblasts in
IPF lungs [7]. Continuous intravenous infusion of polyethylene glycol
catalase blocks asbestosis in a rat model [20]. More recently,
intratracheal catalase administration to asbestos-treated mice was
shown to prevent pulmonary ﬁbrosis by inhibiting H2O2 production
through Rac 1-activated inﬂammatory cells [18].
2.3.2. Glutathione
Glutathione, a low molecular weight antioxidant found in normal
lungs, is reduced in the epithelial lining ﬂuid and ﬁbrotic foci in IPF
lungs [7,37]. The anti-ﬁbrotic effects of N-acetyl cysteine (NAC), a GSH
precursor, are observed in rodent models of ﬁbrosis in which NAC
increases lung GSH levels and attenuates bleomycin-induced ﬁbrosis
[38,39]. Administration of aerosolized NAC to patients with IPF
augments their antioxidant/oxidant balance [40]. One phase III clinical
trial suggested a possible beneﬁt of NAC therapy [41]. However, the
results of an ongoing NIH-sponsored, multi-center, Phase III trial (PAN-
THER) should deﬁnitively address whether NAC is efﬁcacious in IPF.
2.3.3. Superoxide dismutase
SOD decomposes superoxide radicals to H2O2. All three isoforms of
mammalian SOD (intracellular copper–zinc SOD; mitochondrial
manganese SOD; and extracellular SOD [EC-SOD]) exist in lung cells
but cell-speciﬁc localization and expression varies (see for review:
[2,7]). EC-SOD is highly expressed in the lung and is implicated in
the pathogenesis of ROS-induced pulmonary diseases, including
pulmonary ﬁbrosis [2,7]. EC-SOD is protective in several murine
models of pulmonary ﬁbrosis (e.g. bleomycin, asbestos and radiation)
whereas EC-SOD knockout mice have signiﬁcantly more ﬁbrosis
following exposure to environmental toxins [2,7]. Although beyond
the scope of this review, accumulating evidence demonstrates that
EC-SOD exerts its anti-ﬁbrotic effects, in part by preventing oxidative
degradation of the ECM and release of ECM degradation products that
can augment ﬁbrosis by the effects on lung epithelial, mesenchymal
and inﬂammatory cells [2,7]. The role of the other two SOD isoforms
in the pathogenesis of pulmonary ﬁbrosis is less well understood.
Mitochondial Cu, Zn, SOD−/− mice have less oxidative stress and do
not develop asbestosis [19].
2.3.4. Nuclear factor-erythroid 2-related factor 2
Nrf2 is a transcription factor that is considered the “master regula-
tor” of the antioxidant response (see for review: [42]). When Nrf2 is
released from its negative regulator Kelch-like erythroid cell-derived
protein CNC homology-associated protein 1 in the cytosol, Nrf2 trafﬁcs
to the nucleus and activates the antioxidant response element (ARE)
that controls hundreds of genes, including NAD(P)H quinone-
oxidoreductase 1, antioxidant-related genes involved in glutathione
biosynthesis, Phase II detoxifying “stress response” genes, and genes
limiting the inﬂammatory and ﬁbrotic responses. [42] Several recent
studies underscore the importance of Nrf2 in regulating pulmonary
ﬁbrosis. First, Nrf2 knockout mice are more sensitive to bleomycin-
and paraquat-induced pulmonary ﬁbrosis as compared to wild-type
animals [43,44]. Second, in a study of primary lung ﬁbroblasts cultured
from healthy or IPF patients, decreased Nrf2 expression was associated
with a myoﬁbroblast phenotype (increased α-smooth muscle actin
[α-SMA], and type 1 collagen expression) while Nrf2 activation
increased antoxidant defenses and myoﬁbroblastic de-differentiation
in IPF ﬁbroblasts [45]. Moreover, a Nrf2 activator, sulfaphane, increased
Nrf2 expression in cultured ﬁbroblasts from normal and IPF patients;
effects that were associated with increased expression of antioxidants,
decreased ROS levels, andmyoﬁbroblastic dedifferentiation. Sulfaphane
inhibited TGF-β1-mediated proﬁbrotic effects in both normal and IPF
ﬁbroblasts but not in Nrf-2 knockdown ﬁbroblasts [45]. Resveratrol,
a phytoalexin polyphenol produced by several plants, attenuates
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augmenting Nrf2 levels and downstream antioxidant enzymes [44].
Collectively, these results in animal models suggest that Nrf2 may
be a novel target for IPF therapy as well as other oxidative stress-
induced ﬁbrogenic diseases.
3. The role of ROS and AEC apoptosis in pulmonary ﬁbrosis
3.1. AEC apoptosis is important to the pathophysiology of pulmonary
ﬁbrosis
Cells undergo apoptosis by two mechanisms, the extrinsic (death
receptor) and intrinsic (mitochondria-regulated) pathways. Several
lines of evidence convincingly show that lung epithelial cell death/apo-
ptosis is one of the critical pathophysiologic events limiting normal lung
repair and thereby facilitating pulmonary ﬁbrosis. These studies have
been extensively reviewed in detail elsewhere and will only be brieﬂy
summarized here (see for review: [1,14,21,46,47]). First, patients with
IPF and animal models of pulmonary ﬁbrosis show signiﬁcant lung
epithelial cell injury and apoptosis. In contrast to catastrophic lytic
cell death that can trigger an inﬂammatory response, apoptosis is a
regulated, ATP-dependent process of cell death that results in the
elimination of cells with extensive DNA damage without eliciting
an inﬂammatory response. Second, ﬁbrogenic environmental toxins,
including silica and asbestos, can induce both lytic and apoptotic AEC
death in part by generating ROS derived from the mitochondria or
NOXs. Third, DNA strand break formation, a potent trigger of apopto-
sis, occurs in the AEC of human patients with IPF. p53, a critical DNA
damage response molecule reviewed below (see Section 4), is
activated in patients with IPF and rodent models of asbestosis.
Fourth, several murine models have established that AEC apoptosis
is sufﬁcient for inducing pulmonary ﬁbrosis and that blocking AEC-
targeted apoptosis prevents ﬁbrosis [48,49]. Janssen-Heininger and
colleagues [47] have established that redox-based alterations in the
FAS death receptor by protein S-glutathionylation are required for
mediating extrinsic apoptosis in lung epithelial cells and pulmonary
ﬁbrosis. Fas is S-glutathionylated independently of NOX-induced
ROS after caspase-8 degradation of glutathione reductase 1, thereby
increasing caspase-3 activation and apoptosis. Glutathione reduc-
tase 1 overexpression attenuates S-glutathionylation and attenuates
Fas ligand induced apoptosis and pulmonary ﬁbrosis. In the ER of
lung epithelial cells the Fas-ligand induces Fas glutathionylation
with ERp57 (protein disulﬁde isomerase 3) and glutathione S-
transferase π-1, which subsequently increases caspase-3 and -8
activity, AEC apoptosis, and bleomycin-induced lung ﬁbrosis [50].
Notably, RNAi mediated knockdown of ERp57 and glutathione
S-transferase π-1 attenuates the development of bleomycin-induced
pulmonary ﬁbrosis. Finally, preventing αvβ6 integrin release from
damaged lung epithelial cells, blocks activation of latent TGF-β and
pulmonary ﬁbrosis following radiation or bleomycin exposure [51].
Thus, these studies establish a crucial role of AEC apoptosis in the
pathophysiology of pulmonary ﬁbrosis following exposure to oxidative
stress. Future work is required to further characterize the precise
molecular mechanisms involved and to determine the translational
signiﬁcance of identiﬁed targets in animals exposed toﬁbrogenic agents
and humans with IPF.
3.2. Genetic predisposition to pulmonary ﬁbrosis — role of oxidative
stress and the lung epithelium
IPF appears to have a genetic predisposition in nearly 5% of
patients (see for review: [46]). Numerous mutations are associated
with the development of pulmonary ﬁbrosis, some expressed only
in genes of epithelial cells, and others more ubiquitously expressed.
Mutations in surfactant protein C and A2 genes, which are expressed
only in the alveolar epithelium, are present in unique cohorts offamilial pulmonary ﬁbrosis patients [46]. Mutated surfactant proteins
can induce an ER stress in AEC and this is important in mediating
pulmonary ﬁbrosis (discussed below). The most common gene muta-
tions identiﬁed in familial pulmonary ﬁbrosis are in the telomerase
genes (TERT and TERC), and unlike surfactant proteins, are expressed
outside the lung, especially in stem cells and progenitor cells (see for
review: [52]). Notably, AEC from 60 of 62 patients with IPF had short-
ened telomeres that were b50% of predicted [53]. Since shortened
telemeres are directly associated with aging-related diseases in part
due to oxidative stress, shortened AEC telomeres in IPF may in part ac-
count for their susciptibility to ﬁbrosis following injury [3,52,53]. There
is also some evidence that mitochondrial ROS production is a crucial
determinant of telomerase-dependent senescence [54]. However, addi-
tional genetic and/or environmental factors appear important since
AEC telomerase shortening alone does not promote bleomycin-
induced ﬁbrosis in mice [55]. Polymorphisms in the MUC5B gene
promoter are evident in 38% of patients with sporadic IPF and 34%
of patients with familiar pulmonary ﬁbrosis [56]. Further studies
are necessary to determine how alterations in MUC5B, which is
expressed in the bronchial epithelium but not in AT2 cells, augment
pulmonary ﬁbrosis. It will also be of interest determining how oxi-
dative stress adversely impacts these various mutant genes and
their protein products in the development of pulmonary ﬁbrosis in
animal models as well as in humans.
3.3. Mitochondria-regulated AEC death pathways in pulmonary ﬁbrosis
Diverse ﬁbrotic stimuli (ROS, DNA damage, asbestos, etc.) activate
the intrinsic death pathway by increasing the permeability of the
outermitochondrialmembrane, reducing themitochondrialmembrane
potential (Δψm), and releasing numerous apoptotic proteins, including
cytochrome c (see for reviews: [14,21,46,57–59]). The Bcl-2 family of
–BH3 domain proteins is grouped into a four-class hierarchy dependent
on structure and function (either pro- or anti-apoptotic). Pro-apoptotic
proteins, such as Bax and Bak, can induce outer mitochondrial mem-
brane permeabilization, which is the point of no return in the intrinsic
apoptotic pathway causing the release of apoptogenic molecules from
themitochondria and caspase activation. Pro-apoptotic Bid,which is ac-
tivated by the death receptor pathway and triggers intrinsic apoptosis
by blocking anti-apoptotic molecules enabling Bax/Bak-mediated
apoptosis, is necessary for mediating bleomycin-induced ﬁbrosis in
mice [49]. It will be of interest knowing whether AEC or other cell
types are primarily responsible for mediating the effects of Bcl-2 family
members in pulmonary ﬁbrosis.
Oxidative stress resulting from exposure to asbestos ﬁbers activates
the mitochondrial death pathway in AEC that may be important in the
development of pulmonary ﬁbrosis. Since this area has been extensively
reviewed elsewhere (see for reviews: [1,14,21,46,58,59]), herein we
highlight the evidence with asbestos. Asbestos ﬁbers cause mitochon-
drial dysfunction as evidenced by decreased Δψm, the release of
cytochrome c from the mitochondria into the cytosol, and caspase-9
and 3 (but not caspase-8) activation [60]. These effects are blocked by
phytic acid (an iron chelator), benzoic acid (a free-radical scavenger),
and overexpression of Bcl-XL [60]. A crucial role for mitochondrial
ROS in mediating AEC apoptosis is suggested by two lines of evidence:
(1) asbestos-induced AEC intrinsic apoptosis and p53 activation are
blocked in cells lacking mitochondrial DNA and mitochondrial ROS
production and (2) asbestos induces mitochondrial ROS production
using a highly sensitive rho-GFP probe targeted to the mitochondria
[60–63]. An important role for mitochondrial ROS and p53 inmediating
intrinsic AEC following asbestos exposure is suggested by the protective
effects of pifthrin-alpha, an inhibitor of p53-dependent transcription
[63]. Activated protein kinase delta (PKCδ) migrates to the mitochon-
dria of lung epithelial cells in vitro and in vivo following asbestos
exposure and is necessary for inducing asbestos-induced intrinsic
apoptosis and ﬁbrosis via Bim activation [64,65]. Taken together,
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exposure appear important for inducing p53 activation and intrinsic
lung epithelial cell apoptosis. However, the translational signiﬁcance
of these ﬁndings for pulmonary ﬁbrosis awaits further study.
3.4. AEC ER stress in ﬁbrotic lung injury
Several groups have documented that the alveolar epithelium in
patients with IPF have evidence of ER stress response in cells
undergoing apoptosis [66,67]. However, the pathophysiologic signiﬁ-
cance of these ﬁndings and the role of oxidative stress are uncertain.
The ER primarily regulates protein folding and transport as well as
Ca2+ homeostasis (see for reviews: [58,68]). The ER can modulate
intrinsic apoptosis, but the detailed mechanism underlying crosstalk
between the ER and mitochondria and how this regulates mitochon-
drial metabolism, mitochondrial Ca2+ levels, and cell survival/death
signaling are not fully understood. Close tethering of the ER to the
mitochondria appears crucial for transferring ER-derived Ca2+ that
is important for triggering intrinsic apoptosis [58,69]. Mitofusin 2,
one of the several proteins localized at mitochondrial associated
membranes, physically attaches the mitochondria to the ER and is
crucial for mitochondrial Ca2+ uptake from the ER [58,69]. Exogenous
and endogenous stressors, including mitochondrial ROS production,
augment unfolded protein accumulation in the ER, leading to ER stress
and activation of three unfolded protein response (UPR) signaling path-
ways including: (1) inositol requiring protein 1 (IRE1-α)/X box binding
protein 1 (Xbp-1), (2) activated transcription factor 6, and (3) protein ki-
nase RNA-like endoplasmic reticulum kinase/eukaryotic initiation
factor-2a (see for review: [58,68]). The UPR is vitally important for coor-
dinating numerous adaptive cellular responses that enhance cell survival
in the setting of oxidative stress and other noxious stimuli, but apoptosis/
autophagy (cell deathwith extensive cytoplasmic vacuolization) occur in
the setting of a sustained ER stress response [57,58,68].
The Bcl-2 family members function at both the mitochondria and
the ER, although the precisemolecularmechanisms regulating crosstalk
between these two organelles and the role of oxidative stress are not
fully established [58,59,68,69]. Transient ER Ca2+ release favors
pro-survival signaling within cells while sustained ER Ca2+ release
generally results in intrinsic apoptosis [58,59,69]. Sarcoplasmic ER
Ca2+ATPase (SERCA) overexpression in Bax/Bak double knockout
cells, which are resistant to mitochondria-regulated apoptosis, restores
ER Ca2+ levels and intrinsic apoptotic response following exposure to
oxidative stress [69]. The anti-apoptotic effects of Bcl-2 are linked to
Ca2+ mobilization from the ER to the mitochondrion and blocks
homodimerization of pro-apoptotic Bax that displaces SERCA from the
mitochondrial associated membranes [58,59,69]. Oxidative stress-
induced NF-kB transcriptionally regulates the expression of sigma-1
receptors located in the mitochondrial associated membranes, and
downstream of Bcl-2 expression [70]. ER Ca2+ release to the mitochon-
dria is necessary, but not sufﬁcient for induction of intrinsic apoptosis
by coordination of ER stress survival signals through IRE1-α/TNF associ-
ated factor-2, resulting in increased apoptosis signal regulating kinase 1
and JNK [71].
Accumulating evidence implicate an important role for AEC ER
stress response in patients with IPF and possibly in mediating asbes-
tos pulmonary toxicity. First, as noted above, AECs in patients with IPF
that are undergoing apoptosis co-localize with markers of ER-UPR
stress [66–68]. Second, ER stress augments epithelial–mesenchymal
transition (EMT) and the formation of myoﬁbroblasts, one of the pri-
mary effector cells in IPF [72]. Third, AEC ER stress and EMT can result
from over-expression of a mutant, and accumulation of misfolded
forms of surfactant protein C in the ER and are associated with famil-
ial pulmonary ﬁbrosis [72,73]. Notably, transgenic mice conditionally
expressing mutated SP-C L188Q in their AT2 cells and them exposed to
ER stress (e.g. intratracheal tunicamycin) do not develop pulmonary
ﬁbrosis unless a proﬁbrotic stimuli (e.g. bleomycin) is added [74].Thus, AEC ER stress appears to render the cells susceptible to oxida-
tive stress-induced apoptosis following exposure to environmental
toxins or drugs, and thereby promotes pulmonary ﬁbrosis. As
reviewed elsewhere [14], preliminary studies from our group show
that asbestos-exposed AECs release AEC ER Ca2+ and activate the UPR
signaling proteins (IRE1-α andXbp-1). Further, the ER chemical chaper-
one 4-phenyl butyric acid (4-PBA) abolishes asbestos-induced increases
in IRE1-α andXbp-1, but does not prevent ER Ca2+ release or apoptosis.
A recent study demonstrates that ROS are responsible for mediating
TGF-β-induced UPR and that 4-PBA suppresses both TGF-β-induced
UPR and myoﬁbroblast differentiation [75]. Aging, which is a major co-
factor in the development of IPF, is associated with increased oxidative
stress, a decline in ER protein folding, reduced ability of theUPR tomain-
tain cellular homeostasis during ER stress, and increased AEC apoptosis
following injury (see for review: [1,3,57,68]). Unlike young mice, older
mice challenged with murine gamma herpesvirus 68 (MHV68) develop
lung ﬁbrosis that is associated with increased AER ER stress and apopto-
sis [76]. Taken together, these data show that AEC ER stress occurs in IPF
as well as following exposure to various toxins that can promote ﬁbrotic
remodeling. Fig. 3 illustrates a hypothetical model by which crosstalk
between the ER and the mitochondria prevents AEC apoptosis that can
lead to pulmonary ﬁbrosis. It will be of considerable interest to better
understand the molecular mechanisms by which oxidative stress fol-
lowing exposure to environmental toxins, causes an ER-UPR and apo-
ptosis and also to determine whether modulation of this pathway
affords a unique therapeutic target in the management of pulmonary
ﬁbrosis as well as other ﬁbrotic diseases.
4. Oxidative stress and DNA damage response in pulmonary ﬁbrosis
4.1. Oxidative stress induces a p53-dependent DNA damage response
Oxidative stress activates p53, which is considered the genome
gatekeeper because p53 integrates key signals regulating cellular
responses such as cell-cycle arrest, differentiation, apoptosis, senes-
cence, and antiangiogenesis (see for review: [21,77–81]). p53 is a
transcriptional activator modulating downstream target gene expres-
sion involved in DNA-damage responses and tumor suppression that
are important in preventing the accumulation of gene mutations [82].
As such, p53-dependent DNA damage response following oxidative
stress serves as a barrier to tissue injury/ﬁbrosis and tumor progres-
sion by augmenting DNA repair and/or promoting cell death of cells
with DNA damage that overwhelms the repair mechanisms [78].
The key role of p53 is highlighted by the fact that over half of all
human cancers have p53 mutations and also by the increased cancers
seen in p53 null mice [83]. p53 is also redox sensitive and its
transcriptional function is integrally linked to oxidative stress by
orchestrating downstream cellular effects including the induction of
apoptotic cell death [21,81]. Stabilization of p53 can also promote
further ROS generation via effects on the mitochondria [21,81]. By
regulating thousands of genes, either directly or indirectly, p53
modulates numerous vital cellular roles, including mtDNA mainte-
nance (discussed below) [84,85].
Accumulating evidence implicate p53 in the pathophysiology of
pulmonary ﬁbrosis, including that caused by asbestos [21,63,86–89].
Asbestos increases p53 and p21 expression in lung epithelial andmeso-
thelial cells that result in cell-cycle arrest and apoptosis [63,90–92]. p53
levels are elevated in lung cancers of patients with asbestosis [93], and
p53 point mutations are present in the lung epithelium of smokers and
asbestos-exposed patients [94]. Crocidolite asbestos augments p53 gene
mutations in BALB/c-3T3 cells [95]. In lung-speciﬁc dominant-negative
p53mice, chrysotile asbestos induces TGF-β and other proinfammatory/
ﬁbrotic signaling and increases adenocarcinoma formation [96]. Finally,
gene-expression microarray studies in lung epithelial and mesothelial
cells demonstrate that p53 activation has a very prominent role along
with nearly 2500 other genes of over 54,000 genes proﬁled [97,98].
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DNA-damage response, as it occurswith ﬁbrogenic agents such as asbes-
tos and tobacco smoke.
ROS-induced DNA damage can trigger p53-dependent apoptosis
that may be important in driving a ﬁbrogenic response. Further, p53
can promote additional ROS generation, often via effects on the
mitochondria [77,85]. p53-regulated apoptosis can occur via activat-
ing the intrinsic and extrinsic death pathways either directly or
indirectly via crosstalk with other ROS-activated signaling, such as
MAPK [63,99,100]. Prompt repair of DNA lesions in most instances
will restore the DNA. However, abnormal DNA repair may occur
resulting in gene mutations, chromosomal aberrations and ultimately
cell transformation. Damaged DNA can trigger apoptosis and contrib-
ute to the ﬁbrogenic and malignant potential of oxidative stress
[21,101,102]. A variety of DNA lesions, such as single or double strand
breaks, intra- and inter-strand cross-linking and base damage pro-
duced by oxidant-induced ROS induce a DNA damage response
[77,103]. Under normal conditions, p53 expression is maintained at
low levels through constitutive degradation by mouse double-
minute 2 protein (MDM2), an E3 ubiquitin ligase, whereas upon
DNA damage, p53 is released from MDM2-mediated degradation
and is rapidly stabilized [104–106]. Further, deubiquitinating enzymes
including herpesvirus-associated ubiquitin-speciﬁc protease (HAUSP)
and ubiquitin speciﬁc peptidase (Usp) 10 have been shown to stabilize
p53 protein by antagonizing MDM2-dependent ubiquitination in re-
sponse to DNA damage [104,107]. Transcriptional activity of p53 is
also regulated by interacting partners such as transcriptional
coactivators or corepressors [108]. The functional consequences of
DNA damage-dependent p53 stabilization and transcriptional activa-
tion are induction of downstream target genes, such as p21, Bax, Noxa
and BBC3 (encoding PUMA), that are involved inmediating p53's cellu-
lar functions noted above [98,105]. p53 also modulates apoptosis, at
least partially, via transcription-independent mechanisms through
associations with several members of the Bcl2 family of proteins in
the cytoplasm or at the mitochondria [80,101]. As illustrated in Fig. 4,
p53-Bcl2 and/or p53-BclXL complexes can promote Bax- and/or Bak-
mediated intrinsic apoptosis; supporting a dual role of p53 in gene
transactivation as well as in mitochondria-regulated apoptosis [80,109].
To maintain the appropriate cellular redox state, ROS levels are
tightly controlled; a task which is performed by two p53-regulated
interconnected systems: thioredoxin and glutathione [79,110]. The
anti-apoptotic function of p53 is attributed to the effects on genes reg-
ulating the thioredoxin and glutathione systems including glutathioneEnvironmental Toxin Exposure
Adaptive response
-Transient Ca2+ release
-UPR
Apoptotic response
-Sustained Ca2+ release
-UPR
ER stress
Mitochondria: ROS
Apoptosis
Fibrosis
Bax/Bak
Fig. 3. Hypothetical model of AEC ER-mitochondria crosstalk-induced apoptosis and ﬁ-
brosis. Exposure of AECs to environmental toxins induces ER that can lead to the re-
lease of ROS from the mitochondria that promotes apoptosis and pulmonary ﬁbrosis
(see text for details).peroxidase, manganese SOD, aldehyde dehydrogenase 4, p53-induced
glycolysis, apoptosis regulator, PA26 and Hi95 [79].
4.2. The role of p53 during DNA repair triggered by oxidative stress
Damaged DNA following oxidative stress and other genotoxic
exposures can be corrected by p53-related repair systems; a clearly
protective role for p53 [79]. The observation that p53 translocation
to the mitochondria does not necessarily lead to apoptosis and may
enhance mtDNA repair also suggests an important role for p53 in
maintaining normal cellular homeostasis in the setting of oxidative
stress [84,85,111]. Further, there appear to be distinct genes activated
by p53 for mediating the DNA damage response and tumor suppres-
sion following exposure to genotoxic stress as it occurs with ROS [82].
p53 transactivation-dependent and -independent functions act as
coordinators of the DNA repair process and involve most of the
cellular DNA repair systems, such as mismatch repair, non-
homologous end-joining, homologous recombination, nucleotide
excision repair, and base excision repair (BER) [112]. Deﬁciency of
components of the BER induced by oxidative stress, such as
apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1)
or DNA polymerase β, causes a p53-dependent pre- and postnatal
lethality, respectively, and leads to hypersensitivity toward certain
types of DNA-damaging agents [79]. APE/Ref-1 or 8-oxoguanine-DNA
glycosylase (OGG1), another important BER enzyme, is up-regulated
in various cancers and promote apoptosis resistance [112,113]. OGG1
has glycosylase activity that removes abnormal bases in DNA, especially
8-hydroxyguanine (8-oxoG), and generates an apurinic or apyrimidinic
(AP) site recognized by themultifunctional enzymeAPE/Ref-1 [112]. Ox-
idative stress causes multiple types of DNA base damage, however
8-oxoG has been most widely studied since 8-oxoG pairs with adenine
rather than cytosine during DNA replication potentially resulting in a
G:C to T:A transversion that is a pre-mutagenic lesion implicated in
cancer and aging [21,114]. Notably, p53 activation by oxidative stress
in vitro enhances the excision of 8-oxoG nucleotides from the DNA by
enhancing the sequential activities of OGG1 and APE/Ref-1 [81]. The
transactivation-independent functions of p53 during DNA repair and
recombination are also involved during p53-induced apoptosis [113].
Although much has been uncovered recently in how p53 regulates
DNA repair in the setting of oxidative stress, the precise molecular
pathways and their in vivo relevance in the setting of pulmonary ﬁbrosis
are not ﬁrmly established.
Mitochondrial ROS production following oxidative stress causes
mtDNA damage that must be efﬁciently repaired or else mtDNA
damage will trigger cell death or possibly mutagenic abnormalities
contributing to the ﬁbrogenic and malignant potential of ROS
[21,114,115]. The mtDNA is particularly vulnerable to oxidative attack
given its location at the inner mitochondrial membrane in close prox-
imity to the mitochondrial electron transport chain and given that
~1–5% of total molecular oxygen used by the mitochondria for energy
production results in the generation of ROS [21,114–117]. Malignant
transformation involves periods of increased mitochondrial ROS pro-
duction when select cells survive oxidative stress-induced cell death
[115,116,118]. As recently reviewed [21,114,115,119], several lines
of evidence suggest that mtDNA oxidative injury triggers apoptosis
that is important in driving ROS-induced ﬁbrogenesis and, perhaps,
inﬂammation-associated cancers including: (1) cell death is better
associated with mtDNA oxidative lesions than with nuclear DNA
damage, (2) mtDNA damage results in ATP depletion and mitochon-
drial dysfunction, (3) augmenting mtDNA repair can block apoptosis,
and (4) defective mtDNA repair promotes apoptosis. Because mtDNA
oxidative damage is primarily repaired by BER, defects in mitochon-
drial BER enzymes, all of which are encoded in the nucleus and
imported into the mitochondria, can promote mtDNA damage and
instability [114,120]. We focus on mitochondrial Ogg1 (mt-Ogg1)
since it is the best-characterized mitochondrial BER enzyme involved
p53
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Fig. 4. Hypothetical model of p53-dependent cytosolic and mitochondrial apoptotic pathways. In response to stressors such as oxidative stress, nuclear-localized p53 induces the
transcription of target genes that mediate p53's function (see text for details).
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4.3. The role of hOgg1 during mitochondrial DNA repair caused by oxida-
tive stress
The ﬁrst step of the BER involves recognition and removal of the
aberrant 8-oxoG base pair catalyzed by DNA glycosylases, such as
Ogg1. DNA glycosylases recognize the modiﬁed or inappropriate base
and cleave the N-glycosidic bond, creating an abasic site [114]. Notably,
in vitro ﬂuorometric techniques document that oxidative stress prefer-
entially activates mt-Ogg1, rather than nuclear Ogg1 [121]. Further,
Ogg1-deﬁcientmice have increased 8-oxoG levels inmtDNA and nucle-
ar DNA suggesting the importance of Ogg1 for most of the BER activity
following exposure to oxidative stress [122]. An emerging role for
mt-Ogg1 in regulating apoptosis is suggested by the ﬁndings that
mt-OGG1 overexpression reducesmtDNAdamage and intrinsic apopto-
sis caused by ROS-exposed vascular endothelial and asbestos-exposed
cells [61,123–129]. Crocidolite asbestos ﬁbers, which are among the
most potent amphiboles for inducing ﬁbrosis and malignancies, cause
preferential mtDNA damage, rather than nuclear DNA damage, in lung
mesothelial cells that results in apoptosis [129]. The human OGG1
gene produces two major-alternatively spliced OGG1 mRNAs in
humans: α-Ogg1, and β-Ogg1 [130]. α-Ogg1 is mainly located in the
nucleus and present to a lesser extent in the mitochondria whereas
β-Ogg1 is localized exclusively in mitochondria [130,131]. A curious
unexplained observation is that β-Ogg1 levels in the mitochondria are
20-fold higher than α-Ogg1 levels, yet only the α-Ogg1 isoform has
8-oxoG DNA repair glycosylase activity [132]. We reasoned that there
must be a role for Ogg1 that is independent of DNA repair [61]. Support
for this possibility was our observation that overexpression of mito-
chondrial α-Ogg1 mutants lacking 8-oxoG DNA repair activity was as
effective as wild type mt-Ogg1 in preventing oxidant (asbestos and H-
2O2)-induced caspase-9 activation and intrinsic apoptosis in AECs yet
did not affect the levels of mitochondrial ROS production [61]. It is
unclear whether β-Ogg1 acts similarly in preventing oxidant-induced
mitochondrial dysfunction and apoptosis. Interestingly, overexpression
of mitochondrial α-Ogg1 preserved mitochondrial aconitase (ACO2)protein levels and activity in the setting of oxidative stress suggesting
a novel role for Ogg1 that is considered in more detail below [61].
ACO2, which is an essential mitochondrial enzyme for energy
metabolism and involved in the interconversion of citrate to isocitrate
in the tricarboxylic acid (TCA) cycle, contains four iron–sulfur moie-
ties which render ACO2 as a source for ROS and iron in vitro and in
vivo [133–136]. ACO2 is uniquely sensitive to O2•− mediated oxida-
tive inactivation because of the presence of a single unligated iron
atom, such that oxidation of the [4Fe−4S]2+ cluster renders it unsta-
ble and promotes removal of the labile iron atom, consequently
forming H2O2 by the reduction of O2• [135]. Inactivation of ACO2
reduces mitochondrial manganese SOD levels [137], decreases the
life span in Drosophila [134], and may have a pathophysiologic role
in neurodegenerative diseases such as progressive supranuclear
palsy [138], Friedreich's ataxia [139], and Huntington's disease
[140]. In yeast, ACO2 preserves mtDNA independently of ACO2's
catalytic activity, which was the ﬁrst suggestion of a novel dual func-
tion for ACO2 in mtDNA maintenance as well as a mitochondrial TCA
enzyme [141]. We reported a novel role for mt-hOgg1 in chaperoning
ACO2 in the setting of oxidative stress that prevents AEC apoptosis
[61]. Notably, several groups have reported that suppression of Ogg1
expression increases oxidant-induced apoptosis [142–144]. Collectively,
these ﬁndings suggest that intrinsic AEC apoptosis following exposure
to oxidative stress is regulated by a novel interaction between mt-Ogg1
and ACO2. However, the role of Ogg1 and ACO2 in mediating pulmonary
ﬁbrosis following AEC apoptosis requires further study.
The precise molecular mechanisms by which mt-hOgg1 and ACO2
interact to prevent oxidant-induced AEC apoptosis are unclear, but
there are at least two possibilities, which are not mutually exclusive.
First, mt-hOgg1 may chaperone ACO2 and thereby block ACO2 oxida-
tive modiﬁcation that results in its degradation by mitochondrial Lon
protease [145]. An example of this mechanism was uncovered with
Friedreich's Ataxia in which ACO2 coprecipitates with a mutant
frataxin incapable of preventing oxidative inactivation of ACO2
[146]. Frataxin, which is an iron chaperone protein that blocks ACO2
oxidative inactivation and/or augments ACO2 reactivation, may func-
tion similarly to mt-hOgg1. Second, overexpression of mt-hOgg1 or
ACO2 may preserve the mtDNA levels necessary to prevent activation
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may attenuate the accumulation of mtDNA lesions in the setting of
oxidative stress that can result in intrinsic apoptosis via p53-
dependent DNA damage signaling. Support for this latter possibility
includes accumulating evidence showing a potentially crucial associ-
ation between p53, Ogg1 and ACO2. p53 regulates the transcription of
the OGG1 gene in colon and renal epithelial cells [142]. Further, p53
deﬁcient cells have reduced expression and activity of OGG1 due
partly because of reduced p53 binding to the putative cis elements
within the OGG1 promoter; a defect that can be overcome by p53
overexpression. p53 may also modulate ACO2 since thymoquinone,
a p53-dependent antineoplastic drug, decreases ACO2 activity in
liver mitochondria [147]. Both endogenous p53 induction by
camptothecin and exogenous transient p53 overexpression decrease
ACO2 gene expression in prostate carcinoma cells [148]. Camptothecin
does not affect ACO2 reporter activity in p53-null PC-3 cells suggesting
that the decrease in ACO2 gene expression by camptothecin occurs via
p53 activation. These ﬁndings may account for the observation that
Ogg1 decreases oxidative stress-induced ﬁbroblast apoptosis through
p53-mediated signaling [142]. Additional investigations are warranted
to further explore these various possibilities and to determine the mo-
lecular mechanism by which mt-hOgg1 interacts with aconitase to af-
fect p53 signaling. The in vivo relevance of these ﬁndings to oxidative
stress-induced ﬁbrosis also requires study.
5. Oxidative stress and TGF-β-induced ﬁbrosis
The interactive effects between oxidative stress and TGF-β are
important for promoting ﬁbrosis (see for review: [12]). TGF-β,
which is the most potent proﬁbrogenic cytokine evident in nearly
all ﬁbrotic diseases, is a multi-function protein that exists in different
isoforms (TGF-β 1, 2, and 3) and plays a vital role in ECM deposition
by regulating crucial cellular activities such as cell proliferation,
differentiation, adhesion, migration, apoptosis, and EMT. TGF-β stim-
ulates ROS production leading to oxidative stress while oxidative
stress can activate latent TGF-β setting up a vicious proﬁbrogenic
circle. Considerable evidence ﬁrmly implicate that TGF-β is required
for the development of ﬁbrosis including: (1) There is an increase in
TGF-β mRNA and/or protein expression in ﬁbrotic diseases of almost
all organ systems in humans and in experimental animal models of
ﬁbrosis. (2) Transgenic mice that overexpress activated TGF-β global-
ly have ﬁbrosis in multiple organs and tissue. (3) Increased constitu-
tively active TGF-β in lungs and peritoneum leads to lung and
peritoneal ﬁbrosis, respectively. (4) Fibrosis is attenuated in experi-
mental animal models by blocking activated TGF-β in various organ
systems by administration of either TGF-β binding proteins, anti-
TGF-β antibody, or TGF-β type 1 receptor, as well as by the
overexpression of dominant-negative TGF-β type 2 receptor [12].
Herein, we focus on some of the recently identiﬁed important molec-
ular pathways by which TGF-β and oxidative stress collude to drive
pulmonary ﬁbrosis.
5.1. ROS activate latent TGF-β and induces TGF-β gene expression
All three isoforms of TGF-β are secreted in an inactive, latent form
attached to a latency association protein (LAP). ROS increase
TGF-β-induced ﬁbrosis in part by activating latent TGF-β by two
proposed mechanisms: (1) directly through oxidation of the LAP
thereby releasing TGF-β and (2) indirectly by ROS-induced activation
of matrix metalloproteinases (MMPs), which then cleave LAP and
release active TGF-β [12]. ROS generated by asbestos ﬁbers can directly
activate latent TGF-β [149]. Using a site mutagenesis approach, a redox
switch located on methionine 252 of the LAP has been identiﬁed as a
possible extracellular ROS-sensor, since mutant LAP were incapable of
ROS-induced TGF-β activation [150].In addition to activating latent TGF-β, ROS can augment gene
expression and secretion of TGF-β in many cell types including AEC
and macrophages (see for review: [12]). Notably, free radical scav-
enging agents, iron chelators, as well as NOX2 null mice all substan-
tially reduce ROS-induced TGF-β gene expression in several
ﬁbrogenic model systems [12]. Also, H2O2 promotes EMT in lung ep-
ithelial cells via a TGF-β1-dependent mechanism [151]. The ﬁbrotic
response caused by adenoviral vectors encoding constitutively
activated TGF-β1 are blocked by concomitant treatment with adeno-
viruses encoding EC-SOD [152]. Collectively, these studies show the
closely linked interactive effects between ROS and TGF-β activation
in promoting pulmonary ﬁbrosis.
5.2. TGF-β increases ROS production
Although ROS promote activation of TGF-β gene expression and
release from LAP, TGF-β can also increase ROS production. TGF-
β-induced generation of oxidative stress occurs in part by decreasing
antioxidant defenses as well as by increasing ROS production. TGF-β
decreases the concentration of important antioxidants in the lungs
and hepatocytes, such as catalase, GSH and SOD, all of which have
the capacity to inhibit ﬁbrogenic responses due to oxidative stress
as discussed in Section 2.3 [12,153]. Intra-nasal instillation of adeno-
viral vectors encoding for constitutively activated TGF-β1 in murine
lungs suppresses enzymes involved in GSH synthesis before the devel-
opment of pulmonary ﬁbrosis and that this occurs by inducing activat-
ing transcription factor 3 (ATF3), a transcriptional repressor involved in
regulation of glutamate–cysteine ligase [13]. These changes in GSH
synthesis result in oxidative stress, lung epithelial cell apoptosis and
pulmonary ﬁbrosis [13].
There are several mechanisms by which TGF-β can augment the
production of ROS that include the following: (1) activating oxidases
in the cell membrane that promote H2O2 release to the extracellular
space in human lung ﬁbroblasts and bovine pulmonary artery endothe-
lial cells; (2) inducingmitochondrial ROS production in part by decreas-
ing complex IV activity in lung epithelial cells and hepatocytes; and (3)
activating Nox4 to generate ROS in various types of cells in vitro and in
vivo [12,154–156]. Taken together, these studies establish that TGF-β
can augment oxidative stress, important in the pathogenesis of pulmo-
nary ﬁbrosis.
5.3. Possiblemechanisms bywhichROSmediates TGF-β-inducedﬁbrogenesis
The detailed molecular mechanisms by which TGF-β promotes
ﬁbrosis are beyond the scope of this report but have recently been
reviewed [12]. Herein we highlight some of the newer ﬁndings
centered on the four possible mechanisms by which ROS mediate
TGF-β-induced ﬁbrogenesis including: (1) activation of ﬁbroblast prolif-
eration and collagen production, (2) induction of EMT, (3) promotion of
epithelial cell apoptosis, and (4) activation of ECM gene expression and
suppression of ECM protein degradation. Using primary human cardiac
ﬁbroblasts, TGF-β increases NOX4 and α-SMA, a myoﬁbroblast marker,
while knockdown of NOX4 by siRNA reduces production of ROS and
expression of α-SMA mRNA suggesting that ROS mediate cardiac ﬁbro-
blast differentiation to myoﬁbroblasts [31]. Further, these investigators
showed that ROS activate Smad2/3 and that activated Smad2/3 alone
can cause cardiac ﬁbroblast differentiation to myoﬁbroblasts. As noted
above (Section 2.2), TGF-β induced NOX4 expression is crucial for me-
diating ROS production that drives myoﬁbroblast activation in the
lungs of patients with IPF and mice with bleomycin-induced ﬁbrosis
as well as increase in AEC apoptosis [33,157]. TGF-β-induced NOX4
expression and oxidative stress also appear important in mediating
hepatocyte apoptosis and liver ﬁbrosis [158,159]. ROS can induce
EMT; a process that results in a loss of epithelialmarkers and acquisition
of mesenchymal phenotype as seen in many ﬁbrotic diseases, including
IPF [160–162]. TGF-β is a key mediator of EMT in vitro [163,164] and in
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oxidants block TGF-β-induced EMT in lung and renal epithelial cells
[151,167]. A recent study demonstrated that TGF-β coordinately regu-
lates EMT by interactions with β-catenin through its interaction with
cAMP-response element-binding protein (CREB)-binding protein
(CBP) in AECs [168]. Using the bleomycin mouse model of pulmonary
ﬁbrosis, these investigators demonstrate that ICG-001, a small molecule
speciﬁc inhibitor ofβ-catenin/CBP interaction, attenuates pulmonary ﬁ-
brosis and α-SMA and collagen induction in AEC. Given the robust
β-catenin signaling in pulmonary ﬁbrosis as well as emerging evidence
of crosstalk between ROS levels and β-catenin signaling pathway, this
suggests a novel mechanistic link that may be relevant to our under-
standing of pulmonary ﬁbrosis [57,168–170].6. Conclusions
Table 1 summarizes some of the important molecular mechanisms
underlying ROS-induced pulmonary ﬁbrosis that we reviewed as well
as some of the crucial areas that require further investigation. Patients
with pulmonary ﬁbrosis have increased oxidative stress as measured
by various techniques as well as reductions in crucial anti-oxidant
defenses. With the possible exception of NAC, none of the strategiesTable 1
Some of the important molecular mechanisms underlying ROS-induced pulmonary ﬁ-
brosis and areas requiring further investigation.
What we know What we need to know
There is increased oxidative stress in
the lungs of patients with
pulmonary ﬁbrosis.
1. What is the most reproducible technique
to quantitate ROS in tissue and BALF?
2. What is the in vivo relevance of these
ﬁndings in the context of treating
pulmonary ﬁbrosis and which cell(s)
should be targeted?
There is decreased antioxidant
defenses in the lungs of patients
with pulmonary ﬁbrosis.
1. What is the best way to quantitate
anti-oxidant defenses in tissue and BALF?
2. What is the in vivo relevance of these
ﬁndings in the context of treating
pulmonary ﬁbrosis and which cell(s)
should be targeted?
Apoptosis of AECs occurs in patients
with IPF and asbestosis.
Is AEC apoptosis essential for mediating
pulmonary ﬁbrosis?
Pulmonary ﬁbrosis is associated with
activation of an ER stress response
that may be due partly to ROS
production.
What is the causal role of ROS in activating
the ER stress response in AEC as well as the
in vivo relevance of ER stress in the context
of treating pulmonary ﬁbrosis?
ROS cause AEC apoptosis in vitro
while AEC apoptosis occurs in
patients with IPF and asbestosis.
Is AEC apoptosis essential for mediating
pulmonary ﬁbrosis?
Asbestos induces AM
Rac1-dependent mitochondrial
ROS production that
is important in murine asbestosis.
What role does AM Rac1 play in humans
with asbestosis, and is it a useful biomarker
of pulmonary ﬁbrosis?
p53-dependent transcription
mediates ROS/asbestos-induced
intrinsic AEC apoptosis in vitro and
is evident in gene-proﬁling studies
of normal and malignant cells.
Is p53-depenedent transcription necessary
for pulmonary ﬁbrosis following ROS ex-
posure in animal models or humans?
Mitochondrial hOgg1 and ACO2
prevent oxidant-induced AEC
mitochondrial dysfunction and
intrinsic apoptosis in vitro.
What is the in vivo relevance of these
ﬁndings in the context of asbestosis and
other forms of pulmonary ﬁbrosis?
ROS activate latent TGF-β, induce
TGF-β gene expression, and
activate ﬁbroblast collagen
production
What is the in vivo relevance of these
ﬁndings in the context of treating
pulmonary ﬁbrosis and which cell(s)
should be targeted?
ROS activates Nalp3 inﬂammasomes. Is Nalp3 activation induced by ROS neces-
sary and sufﬁcient for inducing pulmonary
ﬁbrosis, and if so, which cell is responsible?
Abbreviations: ACO2, mitochondrial aconitase; AEC, alveolar epithelial cell; AM, alveolar
macrophage; BALF, bronchoalveolar lavage ﬂuid; ER, endoplasmic reticulum; hOgg1,
human8-oxoguanine-DNA glycosylase 1; IPF, idiopathic pulmonary ﬁbrosis; ROS, reactive
oxygen.aimed at limiting oxidative stress to date have proven efﬁcacious in
the management of pulmonary ﬁbrosis. A simple imbalance between
ROS levels and anti-oxidant defenses is unlikely to fully account for
the multiple, independently regulated pathways involving various
cells and organelles [1–3]. Targeted anti-oxants to the mitochondria
or limiting NOX4 activation warrant further study. Emerging
evidence demonstrates that mitochondria- and p53-regulated death
pathways as well as ER stress mediate AEC apoptosis, which is an
important early event in patients with IPF and asbestosis, all of
which are modulated by the levels of ROS. There may also be an
important interactive effect among mtOgg1, ACO2, and p53 in
mtDNA repair and oxidant-induced intrinsic apoptosis. It seems likely
that many of the interactive effects among mtOgg1, ACO2, p53, and
intrinsic apoptosis described herein with asbestos ﬁbers will have
important broader implications regarding pulmonary ﬁbrosis and,
perhaps, mutagenesis. Future investigations exploring the role of
these various interactive effects in transgenic animal models and in
humans are warranted. Furthermore, the role of mt-Ogg1 and ACO2
in preventing oxidant-induced mtDNA damage, p53 activation, and
intrinsic apoptosis requires additional study. ROS activate latent
TGF-β, TGF-β gene expression and ﬁbroblast collagen production by
a RhoA-dependent mechanism. Finally, and perhaps most important-
ly, the ROS/pulmonary ﬁbrosis paradigm is shedding light into the
molecular basis underlying ﬁbrosis in other organs involving the
liver, heart and kidney as well as our understanding of tumorigenesis,
for which effective treatment regimens are urgently required.
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